Cargando…

New perspectives in iron chelation therapy for the treatment of Parkinson’s disease

Detalles Bibliográficos
Autores principales:	Nuñez, Marco T., Chana-Cuevas, Pedro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676885/ https://www.ncbi.nlm.nih.gov/pubmed/31290444 http://dx.doi.org/10.4103/1673-5374.259614

Ejemplares similares

New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases
por: Nuñez, Marco T., et al.
Publicado: (2018)

Chelators in the Treatment of Iron Accumulation in Parkinson's Disease
por: Mounsey, Ross B., et al.
Publicado: (2012)

Benefits of Iron Chelators in the Treatment of Parkinson’s Disease
por: Zeng, Xiaoyan, et al.
Publicado: (2021)

Iron chelators or therapeutic modulators of iron overload: Are we anywhere near ideal one?
por: Ghosh, Kanjaksha, et al.
Publicado: (2018)

Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease
por: Grolez, Guillaume, et al.
Publicado: (2015)

Telemedicine in the Management of Parkinson’s Disease: Achievements, Challenges, and Future Perspectives
por: Cubo, Esther, et al.
Publicado: (2022)

Is Chelation Therapy a Potential Treatment for Parkinson’s Disease?
por: Ward, Roberta J., et al.
Publicado: (2021)

Iron Chelators in Treatment of Iron Overload
por: Entezari, Sarina, et al.
Publicado: (2022)

Cell Therapies for Parkinson's Disease
por: Irion, Stefan
Publicado: (2019)

Patient Perspective on Iron Chelation Therapy: Barriers and Facilitators of Medication Adherence
por: Chong, Chia Chee, et al.
Publicado: (2021)

Potential Treatment of Retinal Diseases with Iron Chelators
por: Shu, Wanting, et al.
Publicado: (2018)

Therapeutic Potential of Iron Chelating Therapy: Modification of Disease by Iron Depletion
por: Hershko, Chaim, et al.
Publicado: (1994)

Regional siderosis: a new challenge for iron chelation therapy
por: Cabantchik, Zvi Ioav, et al.
Publicado: (2013)

Objectives and Methods of Iron Chelation Therapy
por: Hershko, C., et al.
Publicado: (2003)

Iron Chelation Therapy in Thalassemia Syndromes
por: Cianciulli, Paolo
Publicado: (2009)

Iron Chelation Therapy in Myelodysplastic Syndromes
por: Messa, Emanuela, et al.
Publicado: (2010)

Myelodysplastic Syndromes and Iron Chelation Therapy
por: Angelucci, Emanuele, et al.
Publicado: (2017)

Perspectives for the association between olfactory disturbances and depression in Parkinson’s disease
por: Ilkiw, Jessica L., et al.
Publicado: (2019)

Stem Cell Transplantation for Parkinson’s Disease: Current Challenges and Perspectives
por: Zeng, Xinlin, et al.
Publicado: (2022)

Perspectives for a new drug candidate for Chagas disease therapy
por: Soeiro, Maria de Nazaré Correia
Publicado: (2022)

Iron, the endolysosomal system and neuroinflammation: a matter of balance
por: Bórquez, Daniel A., et al.
Publicado: (2021)

Potential role of biofeedback therapy for Parkinson’s disease
por: Kotani, Naoya, et al.
Publicado: (2021)

Pharmacogenomics in Parkinson’s disease: which perspective for developing a personalized medicine?
por: Ciccacci, Cinzia, et al.
Publicado: (2019)

Iron chelation in treatment of superficial siderosis
por: Derle, Eda
Publicado: (2018)

Advances in iron chelation therapy: transitioning to a new oral formulation
por: Shah, Nirmish R.
Publicado: (2017)

Adherence to Iron Chelation Therapy and Its Determinants
por: Sidhu, Sukhmani, et al.
Publicado: (2021)

Targeting chaperone-mediated autophagy for Parkinson’s disease therapy
por: Wang, Yi-Ting, et al.
Publicado: (2023)

The Michael J. Fox Foundation’s Strategies for Accelerating Translation of LRRK2 into Therapies for Parkinson Disease
por: Padmanabhan, Shalini, et al.
Publicado: (2020)

Advance in the use of gold nanoparticles in the treatment of neurodegenerative diseases: new perspectives
por: Silveira, Gustavo de Bem, et al.
Publicado: (2021)

A biophysical perspective on the unexplored mechanisms driving Parkinson’s disease by amphetamine-like stimulants
por: Ferreira, Carla, et al.
Publicado: (2021)

Alpha-Klotho in Parkinson’s disease: a perspective on experimental evidence and potential clinical implications
por: Grillo, Piergiorgio, et al.
Publicado: (2022)

New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications
por: Kontoghiorghes, George J., et al.
Publicado: (2021)

A Review on Iron Chelators in Treatment of Iron Overload Syndromes
por: Mobarra, Naser, et al.
Publicado: (2016)

Real world studies are essential for drug therapy in Parkinson’s disease
por: Müller, Thomas
Publicado: (2018)

Genetics provides new individualized therapeutic targets for Parkinson’s disease
por: Garcia, Eric Joshua, et al.
Publicado: (2020)

Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
por: Elli, Elena Maria, et al.
Publicado: (2014)

Korean Guideline for Iron Chelation Therapy in Transfusion-Induced Iron Overload
por: Jang, Jun Ho, et al.
Publicado: (2013)

The gold complex auranofin: new perspectives for cancer therapy
por: Abdalbari, Farah H., et al.
Publicado: (2021)

Can cinnamon bring aroma in Parkinson's disease treatment?
por: Pahan, Priyanka, et al.
Publicado: (2015)

Vibrotactile coordinated reset stimulation for the treatment of Parkinson's disease
por: Tass, Peter A.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9djqnrbmr0k7opf8dtnkelst4v